Crucell licenses STAR technology to XOMA

By Ted A. Knutson

Washington, Jan. 5 - Crucell NV announced Thursday it has signed a non-exclusive STAR research license agreement for the production of monoclonal antibodies and other proteins with Berkeley, Calif.-based XOMA Ltd.

Financial details were not disclosed.

STAR technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins.

Crucell is a Leiden, The Netherlands-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.